Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings results on Wednesday. The life sciences company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.03, FiscalAI reports. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $411.18 million for the quarter, compared to analysts’ expectations of $413.16 million. During the same quarter last year, the company posted ($0.07) EPS.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $13.33 on Wednesday. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -148.09, a P/E/G ratio of 0.71 and a beta of 1.21. The firm has a fifty day moving average price of $15.67 and a 200 day moving average price of $15.55. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60.

Analyst Ratings Changes

A number of brokerages recently commented on IART. Citigroup reaffirmed a “neutral” rating and issued a $15.00 target price (down from $19.00) on shares of Integra LifeSciences in a report on Monday, October 5th. BMO Capital Markets lowered their target price on Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating on the stock in a research report on Monday, October 5th. Truist Financial cut their price target on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating for the company in a report on Wednesday, October 14th. Wells Fargo & Company set a $15.00 price target on Integra LifeSciences in a report on Saturday, October 3rd. Finally, Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Integra LifeSciences presently has an average rating of “Reduce” and an average price target of $16.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.